Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25262348 | 1.00 | CTSK (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL953453 | 1.00 | CTSK (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL15304806 | 0.88 | PPARA (0.44) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL31036464 | 0.87 | CTSK (0.44) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL21938483 | 0.87 | CTSK (0.44) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8270949 | 0.87 | CTSK (0.44) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL527131 | 0.86 | PPARA (0.53) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL580779 | 0.86 | PPARA (0.53) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL588912 | 0.86 | PPARA (0.53) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL12004419 | 0.85 | HDAC4 (0.50) | CTSKCTSSGAAPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250059213-A1 | LONP1 INHIBITORS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024163962-A1 | 3-((1,1-DIOXIDO-2,3,4,5-TETRAHYDROBENZO[F][1,2,5]THIADIAZEPIN-8-YL)OXY)-2-FLUOROACRYLIC ACID DERIVATIVES AS SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) INHIBITORS FOR THE TREATMENT OF CHOLESTASIS | Hemoshear Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-116813505-A | Method for preparing O-methyl-N-carbobenzoxy-L-homoserine | 爱斯特（成都）生物制药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023107470-A1 | LONP1 INHIBITORS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-3191112-A2 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED, S.L. (ES) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038040-A2 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED, S.L. (ES) | 2016-03-17 | — | — | WO | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-0402313-A1 | Novel endothelin derivative | Japat Ltd (CH) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | CTSK 1164/4885CTSS 871/4885MEN1 3531/4885 |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CTSK 2434/4885CTSS 2010/4885MEN1 1366/4885 |
| US-20250059213-A1 | LONP1 INHIBITORS, USES AND METHODS | LONP1, ACAT1, ACAA2 | CTSK 1102/4885CTSS 736/4885MEN1 3542/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | CTSK 2016/4885CTSS 2459/4885MEN1 2661/4885 |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | CTSK 260/4885CTSS 380/4885MEN1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.